ClinicalTrials.gg
Not yet recruitingNCT07945522CASEUpdated Nov 18, 2026

Coffee and Arterial Stiffness Evaluation

An interventional study of Coffee and Control in Cardiovascular (CV) Risk, Cardiometabolic Risk Markers and Cognitive Assessment, sponsored by University of Reading. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 40 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Reading · Not applicable, Interventional, and Prevention

How we know

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Study summary

This study aims to investigate whether twelve weeks of daily coffee consumption can improve blood vessel elasticity (arterial stiffness) in adults typical of the UK population who are currently non-habitual coffee consumers. Additionally, the effects on cardiometabolic disease risk markers, liver health markers, cognitive function and inter-individual genetic variations in response to coffee consumption will be examined.

Read the detailed description

Coffee has gained interest for its role in the prevention of non-communicable diseases such as heart and liver disease. Observational studies have reported that regular coffee consumption (2-4 cups per day) is associated with reduced risk of cardiovascular disease, type 2 diabetes, and overall mortality. However, these observational studies do not prove direct causality, requiring the need for well-designed randomized controlled trials. Additionally, most evidence comes from habitual coffee drinkers, and there is limited understanding of whether introducing coffee to non-habitual consumers can provide similar health benefits, particularly in individuals that are typically reflective of the UK population.

This trial aims to provide direct causal evidence to the potential health effects of coffee consumption on risk markers for the development of cardiometabolic disease (such as type 2 diabetes, heart and liver diseases). To ensure the potential impact of habitual coffee consumption is minimised as a confounding factor, non-habitual coffee consumers (coffee-naïve) will be recruited. To maximise recruitment and adherence in the study, the coffee intervention is being provided in a tablet formulation (as opposed to a liquid drink formulation typical taken). In a previous pilot study conducted in 2025, the biological activity of the coffee tablet formulation is expected to be deemed bioequivalent compared to the liquid drink.

A 2-armed, double-blind, randomized controlled parallel trial will be conducted in participants that reflect the general population (estimated using UK representative data from the National Diet and Nutrition Survey). The primary outcome is the effect of coffee consumption on arterial stiffness (measured by cardio-ankle vascular index (CAVI)), an important prognostic marker of vascular aging and cardiovascular disease. Secondary outcomes will assess the impact of coffee consumption on cardiometabolic disease risk markers, liver health markers, cognitive function and genetic factors driving inter-individual response. This will be compared to a coffee-free control.

Study participation will require two visits to the Hugh Sinclair Unit of Human Nutrition (HSU), University of Reading, UK. For the first visit, participants will arrive having fasted overnight, consumed a standardised evening meal, and having followed lifestyle restrictions in the preceding days. Baseline anthropometric measures, blood pressure, CAVI measures, cognitive functions scores will be performed in addition to collecting a fasting blood sample (up to 50ml in total). Additionally, participants will be asked to provide a 24-hour urine sample during the same visit. At the end of the first study visit, participants will be randomised, stratified by age, gender and body-mass index (BMI), and receive their intervention bottles containing tablets to take on a daily basis over the 12-week study period. The second study visit will repeat the same procedures outlined at the end of 12 weeks.

02

Conditions studied

  • Cardiovascular (CV) Risk
  • Cardiometabolic Risk Markers
  • Cognitive Assessment
  • Liver Functions
  • Arterial Stiffness

Keywords

  • coffee
  • arterial stiffness
  • liver health
  • polyphenols
  • chlorogenic acid
  • caffeine
  • bioactives
  • cardiovascular health
  • cognitive performance
  • cognition
03

In context

Lead sponsor

University of Reading is the lead sponsor of 151 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females
  • Aged between 40 to 75 years
  • Low habitual coffee consumption (less than 3 cups per week) (over the past 4-week period)
  • (BMI) between 18.5-32.0kg/m\^2 (inclusive)
  • Total cholesterol ≤6.5 mmol/L
  • Fasting triglycerides \<1.7 mmol/L
  • Fasting glucose ≤ 6.1 mmol/L
  • Blood pressure 90/60 - 140/90 mmHg (inclusive)

Exclusion criteria

Exclusion Criteria:

  • Sensitivity to coffee or caffeine
  • Regular consumption of caffeinated products or drinks; including tea, energy drinks or caffeine tablets (over 350 mg caffeine per week) or unwilling to stop drinking coffee during the intervention period
  • Current smoking and vaping use
  • Medical history of chronic diseases (cancer, hypertension, type 2 diabetes, ischaemic attacks and/or any other cardiovascular related diseases, gastro-intestinal disorders, hyperlipidaemia, kidney or liver disease)
  • \<115 g/L for females or \<130 g/L for males
  • Prescribed any medication relating to the study outcome measures (such as blood pressure lowering, anti-inflammatories or blood thinners)
  • Current use or past use of antibiotics within 6 months
  • Drinking more than the recommended intake for alcohol (>14 units of alcohol per week)
  • Current undertaking or planning to start a weight reducing regimen
  • Taking any supplements (vitamins, minerals, prebiotics and probiotics)
  • Any other medical history or diet and lifestyle habits or practices that would preclude volunteers from participating in a dietary intervention and metabolic study (e.g. pacemaker)
  • Parallel participation in another intervention study
  • Pregnancy, planning a pregnancy in the next 6 months or breastfeeding
  • NHS blood donation (470 ml) in the last 3 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
65 participants (estimated)

Study arms

  • Active comparator
    Coffee

    This group will consume 5.4g of a commercially available instant coffee, provided in a tablet formulation (9 tablets daily).

    Dietary Supplement: Coffee

  • Placebo comparator
    Control

    This group will consume a coffee-free control, provided in a tablet formulation (9 tablets daily).

    Dietary Supplement: Control

Interventions

  • Dietary supplementCoffee

    Commercially available instant coffee (5.4g), will be provided as 9 tablets (equivalent to 3 tablets per cup, therefore total 3 cups daily). This is to be consumed by the participant on a daily basis for 12 weeks. The intervention can be taken spaced throughout the day as per participant convenience, with a preference of consuming all 9 tablets by 2pm each day.

  • Dietary supplementControl

    Coffee-free control (microcrystallinecellulose (non-active)) will be provided as 9 tablets. This is to be consumed by the participant on a daily basis for 12 weeks. The intervention can be taken spaced throughout the day as per participant convenience, with a preference of consuming all 9 tablets by 2pm each day.

06

What researchers measure

Primary outcomes

  1. Cardio-ankle vascular index

    Cardio-ankle vascular index (CAVI) score will be measured by the attachment of an inflatable blood pressure cuff to each limb (right brachial, left brachial, right ankle, left ankle) and attachment of a PCG microphone (measuring heart sounds during the cardiac cycle) on the sternum using a VaSera VS-2000 device on study visits. No fixed scale range is present, lower scores indicate an improvement in outcome.

    Time frame: Week 0 (baseline), Week 12 (final visit)

Secondary outcomes

  1. Fasting coffee bioactives concentrations and polyphenol metabolite concentrations

    Plasma concentrations of key coffee bioactives (e.g. caffeine, chlorogenic acids, trigonelline) and polyphenol metabolites will be measured from a fasting blood sample collected on study visits. These samples will be analysed via liquid chromatography mass spectrometry, concentration unit of measure (microgram per millilitre).

    Time frame: Week 0 (baseline), Week 12 (final visit)

  2. Fasting lipid profile concentrations

    Serum total cholesterol (TC), triacylglycerol, high-density lipoprotein cholesterol (HDL-C), non-esterified fatty acids and apolipoprotein B will be measured from a fasting blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (micromolar per litre). Low-density cholesterol concentrations will be calculated from TC concentrations and HDL-C concentrations using the Friedewald formula.

    Time frame: Week 0 (baseline), Week 12 (final visit)

  3. Fasting insulin concentrations

    Serum insulin will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay, concentration unit of measure (IU per millilitre).

    Time frame: Week 0 (baseline), Week 12 (final visit)

  4. Fasting glucose concentrations

    Serum glucose will be measured from a fasting blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (millimolar per millilitre).

    Time frame: Week 0 (baseline), Week 12 (final visit)

  5. Fasting Haemoglobin A1C concentrations of glycaemic control measures

    Haemoglobin (Hb) A1C will be measured from a fasting whole blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (%).

    Time frame: Week 0 (baseline), Week 12 (final visit)

  6. Fasting estimate of insulin resistance

    HOMA-IR (Homeostasis model assessment estimated insulin resistance) will be calculated using the fasting glucose and insulin data. Scale range: \<1 - 5+, lower scores indicate an improvement in outcome.

    Time frame: Week 0 (baseline), Week 12 (final visit)

  7. Fasting estimate of insulin sensitivity

    QUICKI (Quantitative Insulin Sensitivity Check Index) will be calculated using the fasting glucose and insulin data. Scale range: \<0.25 - 0.45+, higher scores indicate an improvement in outcome.

    Time frame: Week 0 (baseline), Week 12 (final visit)

  8. Fasting liver enzyme and function concentrations

    Serum alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate transferase (AST), gamma-glutamyl transferase (GGT) and total bilirubin will be measured from a fasting blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (unit per liter).

    Time frame: Week 0 (baseline), Week 12 (final visit)

  9. Fasting concentrations of kidney function measures

    Serum uric acid and creatinine will be measured from a fasting blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (micromolar per litre).

    Time frame: Week 0 (baseline), Week 12 (final visit)

  10. Fasting concentrations of inflammatory markers

    Serum interleukin (IL) 1b, IL-6, high sensitivity C-reactive protein, tumour necrosis factor alpha, intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion protein 1 (VCAM-1) will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay, concentration unit of measure (picogram per millilitre)

    Time frame: Week 0 (baseline), Week 12 (final visit)

  11. Fasting brain-derived neurotrophic factor concentrations

    Serum brain-derived neurotrophic factor will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay.

    Time frame: Week 0 (baseline), Week 12 (final visit)

  12. Fasting vascular endothelial growth factor concentrations

    Serum vascular endothelial growth factor will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay.

    Time frame: Week 0 (baseline), Week 12 (final visit)

  13. Fasting oxidised low density lipoprotein cholesterol concentrations

    Plasma concentrations of oxidised low density cholesterol will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay.

    Time frame: Week 0 (baseline), Week 12 (final visit)

  14. Fasting trimethylamine N-oxide concentrations

    Plasma concentrations of trimethylamine N-oxide will be measured from a fasting blood sample collected on study visits. These samples will be analysed via liquid chromatography mass spectrometry.

    Time frame: Week 0 (baseline), Week 12 (final visit)

  15. Fasting gut hormone concentrations

    Plasma concentrations of C-peptide, gastric inhibitory polypeptide, glucagon-like receptor-1 and ghrelin will be measured from a fasting blood sample collected on study visits. These samples will be analysed via Luminex

    Time frame: Week 0 (baseline), Week 12 (final visit)

  16. Fasting estimated nitric oxide concentrations

    Plasma estimated concentrations of nitric oxide (nitrate and nitrite) will be measured from a fasting blood sample collected on study visits. These samples will be analysed via chemiluminescence/LCMS.

    Time frame: Week 0 (baseline), Week 12 (final visit)

  17. Urinary metabolomics

    Untargeted metabolomics will be performed on pooled 24 hour urine samples collected on day prior to study visits. These samples will be analysed via liquid chromatography mass spectrometry and nuclear magnetic resonance spectroscopy

    Time frame: Week 0 (baseline), Week 12 (final visit)

  18. Urinary creatinine concentrations

    Urinary concentrations of creatinine will be measured from pooled 24 hour urine samples collected on day prior to study visits. These samples will be analysed via clinical chemistry analyser

    Time frame: Week 0 (baseline), Week 12 (final visit)

  19. Urinary F2-isoprostanes concentrations

    Urinary concentrations of F2-isoprostanes will be measured from pooled 24 hour urine samples collected on day prior to study visits. These samples will be analysed via liquid chromatography mass spectrometry.

    Time frame: Week 0 (baseline), Week 12 (final visit)

  20. Identification of gut microbiota composition

    Gut microbiome composition will be identified and assessed using RNA sequencing from a stool sample, provided on day prior to study visits.

    Time frame: Week 0 (baseline), Week 12 (final visit)

  21. Cognitive function

    Assessment of cognitive function will be performed using Millisecond Inquisit 7 software on study visits. No fixed scale range is present, higher scores indicate an improvement in outcome.

    Time frame: Week 0 (baseline), Week 12 (final visit)

  22. Clinic blood pressure

    Blood pressure will be measured using a blood pressure monitor on study visits.

    Time frame: Week 0 (baseline), Week 12 (final visit)

  23. Ankle Brachial Index

    Ankle Brachial Index will be measured by the attachment of an inflatable blood pressure cuff to each limb (right brachial, left brachial, right ankle, left ankle) using a VaSera VS-2000 device on study visits. Scale range: \<0.5 - 1.4+, higher scores indicate an improvement in outcome.

    Time frame: Week 0 (baseline), Week 12 (final visit)

  24. Lean body mass

    Body lean mass will be measured by bioelectrical impedance using the Tanita scale on study visits.

    Time frame: Week 0 (baseline), Week 12 (final visit)

  25. Body fat percentage

    Body fat percentage will be measured by bioelectrical impedance using the Tanita scale on study visits.

    Time frame: Week 0 (baseline), Week 12 (final visit)

  26. Body-mass index

    Height will be measured using a stadiometer on the first study visit. Weight will be measured using the Tanita scale on both study visits.

    Time frame: Week 0 (baseline), Week 12 (final visit)

  27. Hip and waist circumference

    Hip and waist circumference will be measured using a non-stretch tape on study visits.

    Time frame: Week 0 (baseline), Week 12 (final visit)

07

Study locations

1 site
  • Hugh Sinclair Unit of Human Nutrition
    Reading, Berkshire RG6 6DZ, United Kingdom
    • Sandra Ilett · Contactnutritionvolunteers@reading.ac.uk · 0118378
    • Kim G Jackson, PhD · Sub investigator
    • Anisha Wijeyesekera, PhD · Sub investigator
    • TiJesu Akeredolu, MPharm · Sub investigator
    • Lolwa Alawadhi, MSc · Sub investigator
    • Altaf Farraj, MSc · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — All anonymised IPD that underlie results in a publication and analytical code for statistical analysis

Supporting information: Study protocol, Analytic code

Time frame: Anonymised data will be made available on reasonable request to the study Chief Investigator one year after manuscripts have been published.

Access criteria: For data sharing and preservation, anonymised IPD will be archived in the University of Reading Research Data Archive. Access will be overseen by the project Chief Investigator (Associate Professor Charlotte Mills).

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Jul 2027, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Nov 18, 2026
StartEst.
Nov 15, 2026
Primary completionEst.
Jul 30, 2027
CompletionEst.
Aug 30, 2030
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945522
Responsible party
Charlotte E Mills (Associate Professor, University of Reading) — Principal investigator
First posted
Nov 18, 2026
Start date
Nov 15, 2026 (estimated)
Primary completion
Jul 30, 2027 (estimated)
Completion
Aug 30, 2030 (estimated)
Last update
Nov 18, 2026

Study contacts

Charlotte E Mills, PhD
Contact
c.e.mills@reading.ac.uk
0118378 ext. 7108
Kim G Jackson, PhD
Contact
k.g.jackson@reading.ac.uk
0118378 ext. 5361
Abbe Davy, BSc
study director · University of Reading

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Coffee

Start the discussion